Public Sector Pension Investment Board Buys 13,953 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• The Public Sector Pension Investment Board increased its stake in LeMaitre Vascular, Inc. by 27.4%, acquiring an additional 13,953 shares for a total of 64,929 shares valued at approximately $5.4 million.
• LeMaitre Vascular announced a quarterly dividend of $0.20 per share, representing an annualized dividend of $0.80 and a yield of 0.8%, with the payment date set for September 4th.
• Analysts have recently upgraded their ratings for LeMaitre Vascular, with Cantor Fitzgerald and Barrington Research both setting a target price of $95.00, reflecting a positive outlook on the company.

Public Sector Pension Investment Board raised its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 27.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,929 shares of the medical instruments supplier's stock after buying an additional 13,953 shares during the period. Public Sector Pension Investment Board owned 0.29% of LeMaitre Vascular worth $5,448,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock valued at $9,385,000 after buying an additional 3,248 shares in the last quarter. Invesco Ltd. boosted its position in LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after buying an additional 58,720 shares in the last quarter. Compass Planning Associates Inc boosted its position in LeMaitre Vascular by 91.4% in the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock valued at $988,000 after buying an additional 5,623 shares in the last quarter. US Bancorp DE boosted its position in LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 368 shares in the last quarter. Finally, Johnson Investment Counsel Inc. boosted its position in LeMaitre Vascular by 34.8% in the first quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock valued at $2,469,000 after buying an additional 7,603 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Insider Activity

In related news, Director David B. Roberts sold 10,815 shares of the business's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the transaction, the director owned 17,976 shares in the company, valued at $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 100,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the completion of the transaction, the chief executive officer owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock worth $11,280,206 in the last three months. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Trading Up 3.2%

LMAT stock traded up $3.06 during midday trading on Friday, hitting $99.51. The stock had a trading volume of 40,533 shares, compared to its average volume of 189,400. The firm has a market cap of $2.25 billion, a P/E ratio of 48.31, a price-to-earnings-growth ratio of 2.49 and a beta of 0.79. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The business has a fifty day moving average price of $85.60 and a two-hundred day moving average price of $86.47.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular's revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date is Thursday, August 21st. This represents a $0.80 annualized dividend and a yield of 0.8%. LeMaitre Vascular's payout ratio is presently 38.83%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald lifted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $97.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.